Kellerer M, Kaltoft MS, Lawson J, Nielsen LL, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab 2022 May 11. doi: 10.1111/dom.14765.
PMID: 35546450